Document is current
Any future updates will be listed below
-
Authors
Cohn, Julia G. https://orcid.org/0000-0002-8733-4278
Locke, Susan C. https://orcid.org/0000-0002-0948-4238
Herring, Kris W. https://orcid.org/0000-0001-5628-3423
Dent, Susan F. https://orcid.org/0000-0002-9183-9340
LeBlanc, Thomas W. https://orcid.org/0000-0002-0546-7895
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 4 August 2025
First Online: 16 August 2025
Declarations
:
: SCL acknowledges research funding from AbbVie, BMS, GSK and Jazz Pharmaceuticals. SFD has received honoraria for consulting/advisory boards from Astra Zeneca, Novartis, Eli Lilly, Gilead Sciences, Pfizer, Myocardial Solutions. TWL has received honoraria for consulting/advisory boards from AbbVie, Agilix, Agios/Servier, Apellis, Astellas, AstraZeneca, Beigene, BlueNote, BMS/Celgene, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; speaking related honoraria from AbbVie, Agios, Astellas, BMS/Celgene, Incyte, and Rigel; equity interest in Dosentrx and ThymeCare (stock options in a privately-held company); royalties from UpToDate; research funding from the AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, GSK, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research/National Institutes of Health, and Seattle Genetics.
: Approval was granted by the Duke University Health System Institutional Review Board.
